MYC with TP53 was identified as a network hub in proteomic of hematopoietic progenitors from CML patients [8], and MYC has been demonstrated to be implicated in CML therapy resistance [11]. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.